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Introduction: Historically, Candida albicans has represented the most common cause of candidemia. However, the
proportion of bloodstream infections due to non-albicans Candida species has increased. Because of the risk for
candidemia in intra-abdominal surgical patients, some experts advocate the use of fluconazole prophylaxis. The
impact of this practice on the distribution of Candida species isolated in breakthrough fungal infections in this
population is unknown. We examined the association of fluconazole prophylaxis with the distribution of Candida
species in intra-abdominal surgery patients.
Methods: We retrospectively identified cases with a positive blood culture (BCx) for Candida among hospitalized adult
intra-abdominal surgery patients between July 2005 and October 2012. Distribution of Candida species isolated
represented our primary endpoint. Qualifying surgical cases were determined based on a review of discharge
International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes. Patients receiving
low-dose fluconazole prior to the positive BCx with a known indication for prophylaxis including neutropenia,
ICU exposure or history of organ transplantation were classified as prophylaxis. Appropriateness of fungal treatment
was determined by the timing and selection of antifungal agent based on fungal isolate.
Results: Among 10,839 intra-abdominal surgery patients, 227 had candidemia. The most common Candida species isolated
was C. albicans (n = 90, 39.6%) followed by C. glabrata (n = 81, 35.7%) and C. parapsilosis (n = 38, 16.7%). Non-albicans
Candida accounted for 57.7% of isolates among the 194 non-prophylaxis patients and 75.8% among the 33 prophylaxis
patients (P = 0.001). C. glabrata, the most common non-C. albicans species, was more prevalent than C. albicans in
persons given prophylaxis, but not in those without prophylaxis. A total of 63% of those with candidemia were treated
inappropriately based on the timing and selection of antifungal administration.
Conclusions: Selection pressure from fluconazole prophylaxis in at-risk surgical patients may be associated with a drift
toward fluconazole-resistant species in subsequent candidemia. Tools are needed to guide appropriate treatment
through the prompt recognition and characterization of candidemia.Introduction
With crude mortality approaching 40%, candidemia con-
tinues to take a high toll among certain groups of hospital-
ized patients [1-5]. In the past, the species most frequently
responsible for candidemia and invasive Candida infections
was Candida albicans [1]. Over time, however, there has* Correspondence: evimedgroup@gmail.com
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article, unless otherwise stated.been a shift in the epidemiology of invasive Candida infec-
tion, with an increasing proportion being due to species
other than C. albicans [2,3].
Invasive Candida is of particular concern in specific pop-
ulations. Intra-abdominal surgery is a well-recognized risk
factor for invasive fungal infection [6,7]. The initial choice
of an antifungal is critical in the setting of suspected candi-
demia, as it is strongly associated with the outcomes. Al-
though well-established evidence-based clinical guidelinestral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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propriate and timely initial antifungal therapy have been
complicated by the shifting microbiology and antifungal
susceptibility patterns. To address this uncertainty, the
guidelines recommend empiric therapy with an echino-
candin to treat suspected candidemia in the setting of crit-
ical illness, as well as in neutropenia with fluconazole
prophylaxis, where non-C. albicans isolates are more
likely [8]. Unfortunately, candidal microbiology and thus
initial coverage decisions are less clear in the setting of
intra-abdominal surgery. One factor that may be driving
shifts in candidal populations and antifungal susceptibility
among these patients is fluconazole prophylaxis, which
although controversial is used nevertheless. The con-
cern stems from several studies in nonsurgical cohorts
that have detected an association between fluconazole
prophylaxis and increased infection with Candida glabrata
and Candida krusei, reflecting the impact of selection
pressure with fluconazole prophylaxis [3,9-12]. How-
ever, it is unclear whether such selection pressure with
a drift toward azole-resistant species is a factor among
patients undergoing intra-abdominal surgery who de-
velop candidemia.
The primary aim of our study was to examine whether
there is an association between fluconazole prophylaxis
and the distribution of Candida species found in subse-
quent breakthrough candidemia among intra-abdominal
surgery patients. We also assessed the appropriateness of
empiric antifungal therapy among this group of patients
with candidemia based on timing, dose, and susceptibility.
Methods
Study design and data source
We conducted a retrospective multicenter cohort study
using the Cerner Health Facts® database. Health Facts is
a de-identified database built from participating hospi-
tals’ comprehensive medical records, including time-
stamped medication orders and laboratory/microbiology
data, admission, and billing information from affiliated
patient care locations. Data were included from 97 US
hospitals with diversity of geographic location, bed size,
and teaching status. Cerner Corporation (Kansas City, MO,
USA) has established Health Insurance Portability and Ac-
countability Act-compliant operating policies and proce-
dures using statistical methods for de-identification. With
the use of an existing de-identified database, institutional re-
view board oversight was deemed inapplicable under Health
and Human Services 45 CFR 46.101 (a) (4).
Cohort selection and study definitions
We included all adult (age ≥18 years old) hospitalized pa-
tients discharged between July 2005 and October 2012
with International Classification of Disease, Ninth Revision,
Clinical Modification codes for primary or secondarydiagnosis of intra-abdominal infection and an invasive
abdominal surgery (see Additional file 1) [13]. Patients
were included if they had candidemia defined by at
least one positive blood culture (BCx) for Candida and
no BCx with other fungal genera. If patients had more
than one candidemia episode during the study window, only
the first episode was evaluated for inclusion in the cohort.
For purposes of classification and time reference, the draw
time of the first positive BCx for Candida was used.
Fluconazole prophylaxis was defined as having: a low
dose of fluconazole (200 to 400 mg) prior to positive
BCx for Candida with no prior order for a loading dose
of fluconazole or other therapeutic antifungal agent; and
a known indication for prophylaxis including neutro-
penia, ICU exposure, or history of organ transplantation.
A small portion (approximately 8% of the cohort) re-
quired manual assignment by a clinical pharmacist, who
also took other available data elements into consider-
ation (dosage, frequency, and timing with respect to
other antifungals ordered).
Appropriate treatment was defined as an order for a
loading or therapeutic dose of a qualifying antifungal
agent from 96 hours before through 24 hours after posi-
tive BCx for Candida. The antifungal agents evaluated
included azoles, echinocandins, and amphotericin B
compounds. Inappropriate treatment was defined as:
no antifungal treatment; no order of a qualifying antifungal
agent for a therapeutic dose from 96 hours before through
24 hours after positive BCx for Candida; or cultures grew
C. glabrata or C. krusei and the patient was treated only
with fluconazole. Treatment appropriateness was classified
as indeterminate for other scenarios (for example, patients
with orders for a therapeutic antifungal dose more than
96 hours prior to positive BCx for Candida).
Time to surgery was defined by calendar days from
the admission date based on the first surgical procedure
of interest. Encounters were classified as urgent emer-
gent if the admission type was coded urgent/emergent
or the source was the emergency room or trauma center.
Bacteremia required at least one positive BCx for bac-
teria (excluding common skin contaminants) at any time
during the hospital encounter. Baseline laboratory values
were selected as the first value after admission. Respira-
tory failure prior to index culture was defined based on
mechanical ventilation International Classification of
Disease, Ninth Revision, Clinical Modification proced-
ure codes and arterial blood gas values; and cardiac
dysfunction was indicated by orders for intravenous
pressors. ICU exposure was defined based on pharmacy,
microbiology, and laboratory care settings. Comorbid con-
ditions were defined by primary or secondary Inter-
national Classification of Disease, Ninth Revision, Clinical
Modification codes during or within 12 months prior to
the hospital encounter.
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Mean and standard deviation were reported for continu-
ous variables, and frequency and percentage were reported
for categorical variables. Differences between categorical
variables were assessed via chi-squared or Fisher’s exact
tests, while those in the continuous variables were exam-
ined using the Wilcoxon rank-sum test. The level of statis-
tical significance was set at a two-sided alpha value of 5%.Figure 1 Study population and groups. BCx, blood culture.Analyses were performed in SAS version 9.3 (SAS Insti-
tute, Cary, NC, USA).
Results
Study population characteristics
A total of 10,839 patients who underwent intra-abdominal
surgery were identified, and 227 patients (2.1%) had candi-
demia (Figure 1), of whom 33 (14.5%) had undergone
Zilberberg et al. Critical Care 2014, 18:590 Page 4 of 8
http://ccforum.com/content/18/6/590fluconazole prophylaxis (Table 1). Among the 227 candi-
demia patients the mean age was 62.4 years, approxi-
mately one-half were male, and 74% were Caucasian.
Less than 2% of the study cohort had evidence of anti-
fungal therapy within 30 days prior to admission. The
majority of candidemia patients had their positive BCx
for Candida >96 hours after admission. Approximately
one-half of the study population had the first surgical
procedure of interest within 2 days of admission, but
nearly one-half had the first surgery 3 days or more
after admission. Illness severity in the entire cohort
was high, with 54% of the cohort being treated with va-
sopressors and 68% having respiratory failure prior to
positive BCx for Candida. Sixty percent of patients
were treated in an ICU and 40% of the cohort had
bacteremia at some point during the hospital stay.
When comparing 33 prophylaxis patients (distributed
across 18 institutions) with 194 patients who had not
undergone fluconazole prophylaxis (distributed across
47 institutions), illness severity was generally higher in
the prophylaxis group as evidenced by the need for vaso-
pressors (73% vs. 51%, P = 0.02) and by having respiratory
failure (76% vs. 67%, P >0.05) or hematologic dysfunction
(58% vs. 33%, P = 0.007) prior to positive BCx for Candida.
Occurrence of bacteremia was also more frequent among
patients who received fluconazole prophylaxis compared
with those who did not, but this difference did not
reach statistical significance (55% vs. 39%, respectively,
P = 0.098).
The distribution of Candida species found in positive
BCx for Candida is presented in Table 2. Overall, the
most common Candida species was C. albicans, followed
by C. glabrata and C. parapsilosis. However, within the
prophylaxis group, C. glabrata was the most common iso-
late, followed by C. albicans and C. parapsilosis. The pro-
portion of non-C. albicans species was 76% in the
fluconazole prophylaxis group compared with 58% in the
nonprophylaxis group (P = 0.001).
Appropriateness of therapy
One hundred and forty-three patients (63%) met the cri-
teria for inappropriate therapy based on the timing,
dose, and selection of antifungal therapy (Figure 1). Only
30 patients (13%) could be classified as having received
appropriate treatment, with antifungal therapy for the
remaining patients categorized as indeterminate.
Discussion
Our study has confirmed that C. albicans was the most
common species isolate among patients with intra-
abdominal surgery and candidemia (39.6%), followed
closely by C. glabrata (35.7%). Overall, non-C. albicans
species accounted for more than one-half of all isolates
and three-quarters of isolates among those who hadfluconazole prophylaxis. Most alarmingly, based on timing
and selection of empiric coverage, 63% of candidemia pa-
tients received treatment categorized as inappropriate
based on conservative criteria.
There are several implications to the distribution of
non-C. albicans species found among patients with
prophylaxis. Admittedly, patients with prophylaxis who
developed non-C. albicans candidemia were more se-
verely ill than those without prophylaxis, as evidenced
by their need for vasopressors and mechanical ventila-
tion, as well as by their higher likelihood of having
bacteremia. One could hypothesize that such patients
are more likely to have had prior treatment, and not
just prophylaxis, with fluconazole, which may have served
as the stimulus for development of resistant species. Our
data did not allow us to explore their prior exposure to
fluconazole as treatment, an important question to ad-
dress in future studies. However, the increase in resistant
species among patients with prophylaxis also probably
points to the selection pressures inherent in antimicrobial
prophylaxis in this surgical cohort of patients with intra-
abdominal infections, which is not well documented in
prior studies. The risks and benefits of fluconazole
prophylaxis in this group, although controversial, thus
need to continue to be evaluated carefully, given its
propensity to drive a switch to resistant species in this
deadly disease. Importantly, when faced with a patient
who has received prophylaxis, a clinician must con-
sider that such a patient’s risk for a resistant candidemia
may be considerably elevated and factor this information
into his/her empiric treatment decisions.
Controversy remains regarding antifungal prophylaxis
among intra-abdominal surgery patients. Research efforts
to resolve these questions are impeded by the need for
large sample sizes to demonstrate adjusted differences in
clinical outcomes. Changing Candida epidemiology fur-
ther complicates research and renders some prior studies
obsolete. While shown effectively to decrease the inci-
dence of fungal infection in high-risk, critically ill surgical
patients [9,14-16], fluconazole prophylaxis does not ap-
pear to improve their survival [9,16]. These studies indi-
cate that the benefit to the patient of the decision to use
prophylaxis may not exceed the risk of driving the escal-
ation of resistance to existing antifungal treatments. Our
data indicate that although only a small proportion of this
surgical population received prophylaxis, their risk of a re-
sistant candidal species was high.
While earlier studies reported that non-C. albicans
species accounted for one-half or fewer of isolated or-
ganisms [17,18], later research uncovered an increase in
cases of candidemia involving non-C. albicans [2,3]. We ob-
served a similarly increased proportion of non-C. albicans
isolates, most pronounced among patients receiving prophy-
laxis with fluconazole. This switch in species is concerning,
Table 1 Patient demographic and encounter characteristics
Variable All candidemia Fluconazole prophylaxis No prophylaxis P valuea
(n = 227) (n = 33) (n = 194)
Age (years) 62.4 (15.0) 61.7 (13.7) 62.5 (15.2) 0.6188
Female gender 118 (52.0%) 20 (60.6%) 98 (50.5%) 0.2835
Race
Caucasian 167 (73.6%) 24 (72.7%) 143 (73.7%) 0.4575
African American 45 (19.8%) 9 (27.3%) 36 (18.6%)
Asian 2 (0.9%) 0 (0.0%) 2 (1.0%)
Other known 9 (4.0%) 0 (0.0%) 9 (4.6%)
Unknown 4 (1.8%) 0 (0.0%) 4 (2.1%)
Admission source
Hospital/other care facility 35 (15.4%) 5 (15.2%) 30 (15.5%) 0.1363
SNF/NH 3 (1.3%) 0 (0.0%) 3 (1.5%)
Emergency room 102 (44.9%) 21 (63.6%) 81 (41.8%)
Other 78 (34.4%) 7 (21.2%) 71 (36.6%)
Unknown 9 (4.0%) 0 (0.0%) 9 (4.6%)
Urgent/emergent admission 142 (62.6%) 28 (84.8%) 114 (58.8%)
Charlson Comorbidity Index score 2.1 (2.4) 2.4 (2.9) 2.0 (2.3) 0.9624
Comorbid conditions
Diabetes 56 (24.7%) 10 (30.3%) 46 (23.7%) 0.4168
Hypertension 83 (36.6%) 10 (30.3%) 73 (37.6%) 0.4192
Coronary artery disease 29 (12.8%) 7 (21.2%) 22 (11.3%) 0.1163
Heart failure 32 (14.1%) 6 (18.2) 26 (13.4%) 0.4657
Prior stroke/TIA 12 (5.3%) 5 (15.2%) 7 (3.6%) 0.0062
COPD/bronchiectasis 36 (15.9%) 6 (18.2%) 30 (15.5%) 0.6927
Encounter events
Bacteremia during index encounter 94 (41.4%) 18 (54.5%) 76 (39.2%) 0.0975
ICU exposure during index encounter 135 (59.5%) 30 (90.9%) 105 (54.1%) <0.0001
Respiratory failure prior to positive BCx for Candida 154 (67.8) 25 (75.8) 129 (66.5) 0.2923
IV vasopressor prior to positive BCx for Candida 123 (54.2) 24 (72.7) 99 (51.0) 0.0207
Baseline laboratory parameters
WBC (k/mm3) 12.8 (8.6) 13.2 (11.2) 12.7 (8.1) 0.597
Neutropenia (ANC <500 cells/mm3) any time 27 (11.9%) 9 (27.3%) 18 (9.3%) 0.0181
Blood glucose (mg/dl) 146.5 (72.2) 145.4 (66.4) 146.7 (73.3) 0.8315
eGFR (ml/minute/1.73 m2) 65.4 (45.8) 69.8 (69.0) 64.6 (40.7) 0.8255
Time from presentation to positive BCx for Candida draw
< 48 hours 16 (7.0%) 1 (3.0%) 15 (7.7%) 0.1914
48 to 96 hours 12 (5.3%) 0 (0%) 12 (6.2%)
> 96 hours 199 (87.8%) 32 (97.0%) 167 (86.1%)
Time from presentation to initial procedure of interest
On the day of admission 70 (30.8%) 10 (30.3%) 60 (30.9%) 0.5945
1 to 2 days 44 (19.4%) 7 (21.2%) 37 (19.1%)
≥ 3 days 113 (49.8%) 16 (48.5%) 97 (50.0%)
Antifungal therapy within 30 days prior to admission 3 (1.3%) 1 (3.0%) 2 (1.0%) 0.3525
Data presented as mean (standard deviation) or number (percentage). ANC, absolute neutrophil count; BCx, blood culture; COPD, chronic obstructive pulmonary
disease; eGFR, estimated glomerular filtration rate; IV, intravenous; SNF/NH, skilled nursing facility/nursing home; TIA, transischemic attack; WBC, white blood cell
count. aP value for the comparison between fluconazole prophylaxis and nonprophylaxis.
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Table 2 Distribution of Candida species based on positive







(n = 227) (n = 33) (n = 194)
n % n % n %
Albicans 90 39.65 8 24.24 82 42.27
Glabrata 81 35.68 16 48.48 65 33.51
Parapsilosis 38 16.74 6 18.18 32 16.49
Tropicalis 14 6.17 2 6.06 12 6.19
Lusitaniae 3 1.32 1 3.03 2 1.03
Dubliniensis 2 0.88 0 0.00 2 1.03
Krusei 2 0.88 1 3.03 1 0.52
Guilliermondii 1 0.44 0 0.00 1 0.52
Other 1 0.44 0 0.00 1 0.52
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exhibit greater resistance to fluconazole and are associated
with worse outcomes when compared with C. albicans [19].
The association of increasingly resistant candidal spe-
cies causing candidemia and their associated worsened
outcomes may be explained by the difficulty of targeting
initial empiric therapy amidst the shifting landscape of
antifungal susceptibility. Many studies in both candide-
mia and other serious infections have noted a significant
and clinically important rise in the risk of death when
the patient does not receive prompt empiric treatment
with an agent that covers the culprit pathogen [20-22].
Guidelines for patients with complicated intra-abdominal
infections [23] recommend antifungal prophylaxis for
healthcare-associated infection and those with severe
community-acquired infection, leading with flucona-
zole. An echinocandin is recommended as initial ther-
apy for critically ill patients, although no guidance is
provided with respect to recent fluconazole prophy-
laxis. The Infectious Disease Society of America Expert
Panel favors echinocandins for treating suspected inva-
sive candidiasis in non-neutropenic patients who are
moderately or severely ill or had recent azole exposure
[8]. Guidelines recommend antifungal agents based on
the Candida isolate or suspected isolate, but delaying ap-
propriate selection until culture results are available or
until the patient is critically ill may be too late [8,23].
More than 60% of our study population failed to receive
appropriate empiric therapy based on timing and coverage
(the latter in those whose BCx grew non-C. albicans spe-
cies). We chose not to evaluate adjusted mortality based
on the appropriateness of treatment due to sample size
considerations in the context of the low percentage of
patients with evidence of appropriate treatment. The
challenges that are leading to inappropriate treatmentsuggest the need for additional improvements to rapidly
recognize and characterize candidemia. Risk stratification
algorithms and emerging diagnostics such as β-D-glucan
may play a role in the future [24-26].
Our study is subject to a number of limitations. As a
retrospective cohort, the study is prone to a number of
biases, most prominently selection bias. To mitigate this
bias, we included all consecutive patients who met our a
priori inclusion criteria. Despite the fact that we started
out with more than 10,000 surgical patients at risk for
candidemia, the final cohort with the infection was rela-
tively small. While it would have been desirable to per-
form several stratified or adjusted analyses, including
those based on dose of fluconazole prophylaxis and year
of data with regard to resistance emergence, this limita-
tion precluded such computations. Because physiologic
parameters needed to derive such severity of illness
scores as the Acute Physiology and Chronic Health
Evaluation II score are not available in the study data-
base, we relied on such markers as the need for the ICU,
vasopressors, and mechanical ventilation as surrogates.
As such, our findings require further exploration in the
context of a validated severity of illness system.
Our data may be particularly prone to misclassification
of several factors. For example, we used a relatively
stringent definition for fluconazole prophylaxis. This was
done in order to increase the specificity of the definition.
As a consequence, we probably misclassified some pa-
tients who did not fit this definition and yet received
prophylaxis as not receiving prophylaxis. We chose spe-
cificity over sensitivity in order to avoid inflating the
magnitude of the differences in the candidal species be-
tween the two groups. As a result, the actual differences
in the prevalence of potentially azole-resistant species
between the groups on and off prophylaxis are probably
even greater than what we have observed. On the other
hand, it remains possible that at least some of the cases
identified as prophylaxis in reality received treatment.
However, the stringent nature of our definition of
prophylaxis should have minimized such misclassifica-
tion. The appropriateness of empiric antifungal therapy
could not be determined reliably in nearly 25% of the
study population based on data elements that were avail-
able. However, even in the unlikely event that all of these
patients could have been ultimately assigned to the ap-
propriate group, this would not detract from the finding
that 63% did not receive appropriate therapy.
A distinct strength of our study, as compared with
prior single-center reports, is its multicenter nature,
which lends generalizability to our findings.
Conclusions
In summary, our study provides further evidence of the
microbiologic shifts in candidemia among a population
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To the best of our knowledge, this is the first study to
examine the association of fluconazole prophylaxis with
the candidal species distribution among intra-abdominal
surgery patients. The result of this examination points to
a likely role for selection pressures in such prophylaxis
patients. In turn, the high prevalence of inappropriate
treatment detected in our study is an important re-
minder for clinicians to consider candidemia in a fitting
clinical setting, and to be aware of the factors that drive
antifungal resistance. Most importantly, in the era of a
widening gap between evolving microbial defenses and
our abilities to address them, antifungal prophylaxis
practices among intra-abdominal surgical patients re-
quire a measured re-evaluation.
Key messages
 C. albicans was the most common fungal isolate among
intra-abdominal surgery patients with candidemia,
followed closely by C. glabrata.
 The percentage of nonalbicans Candida species was
disproportionately high among intra-abdominal surgery
patients treated with fluconazole prophylaxis.
 The shifting epidemiology of fungal species in
intra-abdominal infections and the potential for
selection pressure has significant implications to
prophylaxis therapy and the empiric treatment of
those with suspected infection.
 More than 60% of patients did not receive
appropriate antifungal therapy based on timing and
selection of antifungal agent.
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